跳至主要内容
临床试验/NL-OMON37116
NL-OMON37116已完成不适用

Oxytocin in PTSD: effectiveness as addition to Narrative Exposure Therapy - Oxytocin in PTSD: Effectiveness in addition to NET (OPEN)

Academisch Medisch Centrum0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
24

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 至 99(—)

入选标准

  • - Patients with a diagnosis of chronic PTSD (> 3 months)
  • -CAPS score of - 50
  • -Age 18-65 years
  • -Written informed consent
  • -Eligible for exposure therapy
  • - Capable to read and comprehend either the Dutch or English language

排除标准

  • -Suicidal risk.
  • - Presence of any of the following DSM IV diagnoses, at present or in the past: psychotic disorder incl. schizophrenia, a bipolar disorder, or excessive substance related or eating disorder over the past 6 months.
  • - Female patients being pregnant (NB. female patients with childbearing potential must have a negative pregnancy test each month).
  • - Female patients with an active pregnancy wish.
  • - Female patients giving lactation to their child.
  • - Diagnosis of current severe depressive disorder (with psychotic features and/or high suicidal intent).
  • - An organic disorder/cognitive impairment.
  • - Patients using psychotropic medications will be required to have been on a stable dose for at least 2 months before their pre-treatment assessment (T0). Psychotropic medication already used at the pre-treatment assessment will be maintained until the post-treatment assessment. No psychotropic medication will be prescribed for participants during the study unless they develop serious depressive symptoms. A medication protocol in accordance with clinical guidelines (A.P.A., 2004; Institute of Medicine (IOM), 2008; National Institute for Clinical Excellence, 2005) will be used.
  • -Use of prostaglandins and certain anti-migraine medications (ergot alkaloids), systemic glucocorticoids and beta-blockers.
  • -Sensitivity or allergy for oxytocin or its components (e.g. methylhydroxybenzoaat en propylhydroxybenzoaat)
  • -Evidence of clinically significant and unstable medical conditions in which OT administration is contra-indicative, including cardiovascular, gastro-intestinal, pulmonary, severe renal, endocrine or hematological disorders, glaucoma, history of epilepsy, and stroke or myocardial infarction within the past year.

研究者

相似试验

Oxytocin in PTSD: effectiveness as addition to... | 临床试验